Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells

Journal of Oral Pathology and Medicine

Volumn 42, Issue 7, 2013, Pages 541-546

  Huang, Zhiquan ^a   Wang, Lili ^a,b   Wang, Youyuan ^a   Zhuo, Ying ^a   Li, Haigang ^a   Chen, Ju ^a   Chen, Weiliang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

CD147; Chemotherapy; Cisplatin; Head and neck squamous cell carcinoma; uPAR

Indexed keywords

CD147 ANTIGEN; CISPLATIN; MESSENGER RNA; NEUTRALIZING ANTIBODY;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL SURVIVAL; CHEMOSENSITIVITY; DOWN REGULATION; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CD147; CHEMOTHERAPY; CISPLATIN; HEAD AND NECK SQUAMOUS CELL CARCINOMA; UPAR;

ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84880733066     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12046     Document Type: Article

References (29)

1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 395: 1143-54.
2. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5: 127-35.
3. Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 2006; 1: 285-95.
4. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2644-52.
5. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010; 7: 252-61.
6. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-83.
7. Iacono KT, Brown AL, Greene MI, Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 2007; 83: 283-95.
8. Tsai WC, Chao YC, Sheu LF, et al. EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pan in Chinese people. APMIS 2007; 115: 929-38.
9. Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS. Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 2006; 49: 388-95.
10. Taylor PM, Woodfield RJ, Hodgkin MN, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene 2002; 21: 5765-72.
11. Muramatsu T, Miyauchi T. Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol 2003; 18: 981-7.
12. Zeng HZ, Qu YQ, Liang AB, et al. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance. Neoplasma 2011; 585: 449-54.
13. Als AB, Dyrskjøt L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13: 4407-14.
14. Huang Z, Huang H, Li H, Chen W, Pan C. EMMPRIN expression in tongue squamous cell carcinoma. J Oral Pathol Med 2009; 38: 518-23.
15. Murar S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83: 489-501.
16. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010; 21: 252-61.
17. Argiris A, Karamouzis MV. Empowering induction therapy for locally advanced head and neck cancer. Ann Oncol 2011; 22: 773-81.
18. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518-23.
19. Wang B, Xu YF, He BS, et al. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res 2010; 29: 61.
20. Davidson B, Givant-Horwitz V, Lazarovici P, et al. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in ovarian carcinoma. Clin Exp Metastasis 2003; 20: 621-31.
21. Quemener C, Gabison EE, Naïmi B, et al. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007; 67: 9-15.
22. Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65: 3193-9.
23. Zucker S, Hymowitz M, Rollo EE, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 2001; 158: 1921-8.
24. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003; 1: 420-7.
25. Marieb EA, Zoltan-Jones A, Li R, et al. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 2004; 64: 1229-32.
26. Zhu C, Pan Y, He B, et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells. Oncol Rep 2011; 25: 425-32.
27. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004; 37: 541-8.
28. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008; 14: 5649-55.
29. Smith HW, Marshall CJ. Regulation of cell signaling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.